CVKD Form 144: Proposed Sale of 1,600 Founder Shares ($22K)

Cadrenal Therapeutics (CVKD) filed a Form 144 to notify a proposed sale of 1,600 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $22,000.

Rhea-AI Filing Summary

Cadrenal Therapeutics (CVKD) filed a Form 144 to notify a proposed sale of 1,600 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $22,000. The filing shows 2,046,854 shares outstanding, so the notice covers a very small portion of the company’s outstanding stock. The shares were acquired as founders shares on 05/17/2022 and no payment financing arrangements are indicated. The planned approximate sale date is 08/27/2025. The filer reports no securities sold in the prior three months.

Insights

Financial Analyst

TL;DR: Small proposed sale of founder shares; immaterial to capitalization but worth monitoring for insider liquidity.

The filing notifies a proposed sale of 1,600 common shares valued at $22,000 through Morgan Stanley Smith Barney. Relative to 2,046,854 shares outstanding, this represents a negligible stake, so the direct impact on share supply and market capitalization is minimal according to the document. The shares were acquired as founders shares on 05/17/2022 and no prior sales in the last three months are reported, consistent with limited insider disposition activity disclosed here.

Corporate Governance Expert

TL;DR: Routine Rule 144 disclosure for insider liquidity; no governance red flags evident from this notice.

The Form 144 indicates the seller relies on Rule 144 procedures for disposing of restricted founder shares. The filing includes broker details and an explicit representation that the seller is unaware of undisclosed material adverse information. There are no indications in this notice of unusual trading plans, accelerated dispositions, or aggregated sales in the prior three months. Based solely on this filing, governance implications appear routine and procedural.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filed by CVKD disclose?

The filing discloses a proposed sale of 1,600 common shares valued at $22,000 through Morgan Stanley Smith Barney with an approximate sale date of 08/27/2025.

How many Cadrenal Therapeutics (CVKD) shares are outstanding per the filing?

The filing lists 2,046,854 shares outstanding.

When and how were the shares to be sold acquired?

The 1,600 shares were acquired as founders shares on 05/17/2022, per the filing.

Has the filer sold any CVKD securities in the past three months?

No. The filing states "Nothing to Report" under securities sold during the past three months.

Who is the broker handling the proposed sale?

The broker is listed as Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, New York, NY.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/27/2025 - 04:29 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001401385
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CADRENAL THERAPEUTICS, INC.
SEC File Number	001-41596
Address of Issuer	822 A1A North, Suite 306 Ponte Vedra FLORIDA 32082
Phone	904-300-0701
Name of Person for Whose Account the Securities are To Be Sold	MATTHEW SZOT
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1600	22000.00	2046854	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/17/2022	Founders Shares	Issuer			1600	05/17/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/27/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Matthew Szot
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)